ARCH Venture Partners and Cormorant Asset Management led a $200m Series B round for Erasca, a biotechnology company in San Diego, California. New investors participating in this financing include global Singapore-based investor EDBI, Invus, Terra Magnum Capital Partners, and other private and strategic investors. Existing investors City Hill Ventures, Colt Ventures and LifeSci Venture Partners also participated meaningfully in the round. "We are pleased to continue backing Erasca’s terrific team and bold mission. Cancer is a formidable disease. Therefore, Erasca’s team has built an impressive portfolio of potentially first-in-class and best-in-class assets, including successful in-licensing of several key programs to address significant unmet needs. The company has the talent, assets and perseverance to substantially change the trajectory of cancer treatment and improve patient outcomes in a meaningful way," Kristina Burow, ARCH Venture Partners Managing Director.